FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.624,48 +573,97 (+0,97%)
Prenetics Global Limited (PRE)
Dopo ore:
| Chiusura precedente | 4,9700 |
| Aperto | 4,8600 |
| Denaro | 4,5800 x 400 |
| Lettera | 4,7300 x 100 |
| Min-Max giorno | 4,6100 - 4,9243 |
| Intervallo di 52 settimane | 2,8500 - 15,9000 |
| Volume | |
| Media Volume | 131.057 |
| Capitalizzazione | 56,266M |
| Beta (5 anni mensile) | -0,11 |
| Rapporto PE (ttm) | 1,06 |
| EPS (ttm) | 4,3500 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 60,00 |
GlobeNewswirePrenetics Announces Second Quarter 2023 Financial Results
HONG KONG, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced financial results for the second quarter ended June 30, 2023, along with recent business updates. Second Quarter 2023 Financial Highlights Revenue from continuing operations of US$5.7 millionAdjusted EBITDA from continuing operations of US$(5.3) millionCash and other short-term assets1 of US$214.5 million as of Jun
GlobeNewswirePrenetics and Globally Renowned Scientist Prof. Dennis Lo Establish US$200m Joint Venture “Insighta” for Breakthrough Multi-Cancer Early Detection Screening
Company will Host Conference Call to Discuss the Transaction on June 26 at 8:30 a.m. EDT Prenetics and Globally Renowned Scientist Prof. Dennis Lo Establish US$200m Joint Venture “Insighta” for Breakthrough Multi-Cancer Early Detection Screening (Prof. Dennis Lo and Danny Yeung at Signing Ceremony) (Prof. Dennis Lo and Danny Yeung at Signing Ceremony) - Insighta is a 50/50 Joint Venture by Prenetics and Professor Dennis Lo. - Insighta is powered by technology developed by the Centre for Novostic
GlobeNewswirePrenetics Announces First Quarter 2023 Financial Results
HONG KONG, June 05, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics and precision oncology company, today announced financial results for the first quarter ended March 31, 2023, along with recent business updates. First Quarter 2023 Financial Highlights Revenue of US$17.7 millionAdjusted EBITDA of US$(5.7) millionCash and other short-term assets1 of US$224.1 million as of March 31, 2023 _______________1 Represents current assets,
